Evotec and LEO Pharma form drug discovery alliance targeting dermatological conditions

Hamburg, Germany, and Ballerup, Denmark, 04 Dec 2018

Evotec AG today announced a new integrated drug discovery alliance with LEO Pharma, a global leader in medical dermatology. The collaboration goal is to generate new leads against innovative targets for a range of dermatological conditions and initially runs for two years. The collaboration leverages Evotec’s industry-leading hit identification platform including the extensive screening, structural biology and fragment-based drug design capabilities and expertise together with LEO Pharma’s 110-year track record of drug development and advancing science in dermatology.